August 22, 2014 4:37 PM ET

Biotechnology

Company Overview of CureTech Ltd.

Company Overview

CureTech Ltd., a biotechnology company, develops immune modulating products for the treatment and control of cancer. Its products are antibodies and peptide-based vaccines that are designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner. It develops pidilizumab (CT-011), a humanized monoclonal antibody that interacts with PD-1, a B7 receptor-family-associated protein and exhibits anti-cancer immune response against a range of mouse and human tumors. The company was founded in 2001 and is based in Yavne, Israel.

42 Hayarkon Street

Yavne,  81227

Israel

Founded in 2001

Phone:

972 8 932 4000

Fax:

972 8 932 4001

Key Executives for CureTech Ltd.

Chief Executive Officer
Vice President of Finance
Head of Clinical Development
Vice President of Research & Development
Compensation as of Fiscal Year 2014.

CureTech Ltd. Key Developments

CureTech Ltd. Presents at Biotech Showcase 2014, Jan-15-2014 08:00 AM

CureTech Ltd. Presents at Biotech Showcase 2014, Jan-15-2014 08:00 AM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States. Speakers: Michael Schickler, Chief Executive Officer.

CureTech Ltd. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013

CureTech Ltd. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013 . Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.

Teva Pharmaceutical Industries Announces Termination of Collaboration with CureTech

Teva Pharmaceutical Industries Limited announced the termination of its collaboration with CureTech Ltd. CT-011 is a humanized monoclonal antibody being developed as a treatment for hematological malignancies and solid tumors. CT-011 was assessed in several phase I and II clinical studies in various cancer indications including diffuse large B-cell lymphoma (DLBCL), colon cancer, metastatic melanoma and additional investigator initiated studies. Teva entered into agreements with CureTech in 2006.

Similar Private Companies By Industry

Company Name Region
Lostam BioPharmaceuticals Ltd Middle East/Africa
TheraCoat Ltd. Middle East/Africa
Nutrinia Ltd. Middle East/Africa
Chi2gel Ltd. Middle East/Africa
Slo-Flo Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 17, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CureTech Ltd., please visit www.curetechbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.